Abstract
Background
Multi-class HIV-1 resistant variants are not rare nowadays. Genotypic and phenotypic resistance testing (including virtual phenotype) constitutes an important tool for optimizing antiretroviral treatment.
Aim
To report a case of discrepancy between resistance interpretation and virological outcome.
Methods
A case of a multi-drug experienced patient is presented. Genotypic and/or virtual phenotypic testing analysis was used.
Results
The patient after 10 years of antiretroviral therapy with 11 different regimens unable to produce full virological suppression and with a rapidly declining CD4 count, achieved a successful virological outcome with a scheme containing Tipranavir boosted with low dose of ritonavir. Of note, the patient was screened for Tipranavir 1182.48 study and was found ineligible after genotypic analysis.
Conclusions
Virologic suppression was achieved despite the fact that neither an active agent was included in the backbone regimen nor the resistance profile could ensure the effectiveness of Tipranavir.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Torti C, Quiros-Roldon E, Ragazzi M et al (2005) The resistance and dosage adapted regimens [RADAR] study. CID 40(12):1828–1836
Munoz M, Carmona R, Perez-Alvarez L et al (2005) Analysis of discrepancies in the interpretation of antiretroviral results in HIV-1 infected patients of Basque Country, Spain. J Clin Virol 33(3):224–229
Tural C, Ruiz L, Holzer C et al (2002) Utility of HIV genotyping and clinical expert advice (HAVANA). AIDS 16:209–218
Baxter JD, Merigan TC, Wentworth DN et al (2002) Both baseline HIV-1 drug resistance and antiretroviral drug levels are associated with short-term virologic responses to salvage therapy. AIDS 16:1131–1138
Panidou ET, Trikalinos TA, Ioannidis JP (2004) Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta analysis. AIDS 18(16):2153–2161
Torti C, Quiros-Roldan E, Keulen W et al (2003) Comparison between rules-based HIV-1 genotype interpretation and real or virtual phenotype: concordance analysis and correlation with clinical outcome in heavily treated HIV-1 positive patients. J Infect Dis 188:194–201
Magiorkinis E, Paraskevis D, Magiorkinis G et al (2007) Identification of a single amino acid insertion in HIV-1 protease associated with reduced susceptibility to Lopinavir/r. Poster presentation at the 5th European HIV drug resistance workshop, Cascais, Portugal
Croom KF, Kean SJ (2005) Tipranavir: a ritonavir-boosted protease inhibitor. Drugs 65(12):1669–1677
Acknowledgments
D. P. was supported by the Hellenic Center of Infectious Diseases Control and Prevention (H.C.D.C.P, http://www.keel.org.gr) of the Ministry of Health and Welfare. Potential conflicts of interest. All authors: no conflicts.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Panagopoulos, P., Paraskevis, D., Antoniadou, A. et al. Successful virological outcome in an HIV-infected individual with a three-class resistant variant and an insertion in the protease genome with a Tipranavir based regimen. Ir J Med Sci 179, 305–307 (2010). https://doi.org/10.1007/s11845-008-0211-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-008-0211-6